BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 31326556)

  • 1. Multi-dimensional immunoproteomics coupled with in vitro recapitulation of oncogenic NRAS
    Belousov PV; Afanasyeva MA; Gubernatorova EO; Bogolyubova AV; Uvarova AN; Putlyaeva LV; Ramanauskaite EM; Kopylov AT; Demin DE; Tatosyan KA; Ustiugova AS; Prokofjeva MM; Lanshchakov KV; Vanushko VE; Zaretsky AR; Severskaia NV; Dvinskikh NY; Abrosimov AY; Kuprash DV; Schwartz AM
    Cancer Lett; 2019 Dec; 467():96-106. PubMed ID: 31326556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemical detection of NRAS(Q61R) protein in follicular-patterned thyroid tumors.
    Oishi N; Kondo T; Vuong HG; Nakazawa T; Mochizuki K; Kasai K; Inoue T; Tahara I; Hirokawa M; Miyauchi A; Katoh R
    Hum Pathol; 2016 Jul; 53():51-7. PubMed ID: 26980032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum Immunoproteomics Combined With Pathological Reassessment of Surgical Specimens Identifies TCP-1ζ Autoantibody as a Potential Biomarker in Thyroid Neoplasia.
    Belousov PV; Bogolyubova AV; Kim YS; Abrosimov AY; Kopylov AT; Tvardovskiy AA; Lanshchakov KV; Sazykin AY; Dvinskikh NY; Bobrovskaya YI; Selivanova LS; Shilov ES; Schwartz AM; Shebzukhov YV; Severskaia NV; Vanushko VE; Moshkovskii SA; Nedospasov SA; Kuprash DV
    J Clin Endocrinol Metab; 2015 Sep; 100(9):E1206-15. PubMed ID: 26196948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NRAS Q61R immunohistochemical staining in thyroid pathology: sensitivity, specificity and utility.
    Saliba M; Katabi N; Dogan S; Xu B; Ghossein RA
    Histopathology; 2021 Oct; 79(4):650-660. PubMed ID: 33960437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Constitutive Expression of NRAS with Q61R Driver Mutation Activates Processes of Epithelial-Mesenchymal Transition and Leads to Substantial Transcriptome Change of Nthy-ori 3-1 Thyroid Epithelial Cells.
    Demin DE; Afanasyeva MA; Uvarova AN; Prokofjeva MM; Gorbachova AM; Ustiugova AS; Klepikova AV; Putlyaeva LV; Tatosyan KA; Belousov PV; Schwartz AM
    Biochemistry (Mosc); 2019 Apr; 84(4):416-425. PubMed ID: 31228933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Using immunoproteomics to identify tumor-associated antigens (TAAs) as biomarkers in cancer immunodiagnosis.
    Zhu Q; Liu M; Dai L; Ying X; Ye H; Zhou Y; Han S; Zhang JY
    Autoimmun Rev; 2013 Oct; 12(12):1123-8. PubMed ID: 23806562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serological proteome analysis approach-based identification of ENO1 as a tumor-associated antigen and its autoantibody could enhance the sensitivity of CEA and CYFRA 21-1 in the detection of non-small cell lung cancer.
    Dai L; Qu Y; Li J; Wang X; Wang K; Wang P; Jiang BH; Zhang J
    Oncotarget; 2017 May; 8(22):36664-36673. PubMed ID: 28456790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new method combining sequential immunoaffinity depletion and differential in gel electrophoresis to identify autoantibodies as cancer biomarkers.
    Grandjean M; Dieu M; Raes M; Feron O
    J Immunol Methods; 2013 Oct; 396(1-2):23-32. PubMed ID: 23916966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemistry as a potential tool for routine detection of the NRAS Q61R mutation in patients with metastatic melanoma.
    Ilie M; Long-Mira E; Funck-Brentano E; Lassalle S; Butori C; Lespinet-Fabre V; Bordone O; Gay A; Zahaf K; Poissonnet G; Lacour JP; Bahadoran P; Ballotti R; Gros A; Dutriaux C; Saiag P; Merlio JP; Vergier B; Emile JF; Hofman V; Hofman P
    J Am Acad Dermatol; 2015 May; 72(5):786-93. PubMed ID: 25659223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutation of NRAS is a rare genetic event in ovarian low-grade serous carcinoma.
    Xing D; Suryo Rahmanto Y; Zeppernick F; Hannibal CG; Kjaer SK; Vang R; Shih IM; Wang TL
    Hum Pathol; 2017 Oct; 68():87-91. PubMed ID: 28873354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Autoantibodies against Tumor-Associated Antigens as Potential Blood-Based Biomarkers in Thyroid Neoplasia: Rationales, Opportunities and Challenges.
    Belousov PV
    Biomedicines; 2022 Feb; 10(2):. PubMed ID: 35203677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SP174 Antibody Lacks Specificity for NRAS Q61R and Cross-Reacts With HRAS and KRAS Q61R Mutant Proteins in Malignant Melanoma.
    Felisiak-Goląbek A; Inaguma S; Kowalik A; Wasąg B; Wang ZF; Zięba S; Pięciak L; Ryś J; Kopczynski J; Sarlomo-Rikala M; Góźdź S; Lasota J; Miettinen M
    Appl Immunohistochem Mol Morphol; 2018 Jan; 26(1):40-45. PubMed ID: 29206715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Application of BRAF, NRAS, KRAS mutations as markers for the detection of papillary thyroid cancer from FNAB specimens by pyrosequencing analysis.
    Park SJ; Sun JY; Hong K; Kwak JY; Kim EK; Chung WY; Choi JR
    Clin Chem Lab Med; 2013 Aug; 51(8):1673-80. PubMed ID: 23585181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survey of autoantibody responses against tumor-associated antigens in thyroid cancer.
    Abols A; Ducena K; Zayakin P; Silina K; Kalnina Z; Sadovska L; Tars J; Vilmanis J; Narbuts Z; Eglitis J; Pirags V; Line A
    Cancer Biomark; 2014; 14(5):361-9. PubMed ID: 25171478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autoantibody Biomarker Discovery in Primary Open Angle Glaucoma Using Serological Proteome Analysis (SERPA).
    Beutgen VM; Perumal N; Pfeiffer N; Grus FH
    Front Immunol; 2019; 10():381. PubMed ID: 30899261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autoantibody against Tumor-Associated Antigens as Diagnostic Biomarkers in Hispanic Patients with Hepatocellular Carcinoma.
    Ma Y; Qiu C; Wang B; Zhang X; Wang X; Aguilera RJ; Zhang JY
    Cells; 2022 Oct; 11(20):. PubMed ID: 36291095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRAF and RAS Mutational Status in Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features and Invasive Subtype of Encapsulated Follicular Variant of Papillary Thyroid Carcinoma in Korea.
    Kim M; Jeon MJ; Oh HS; Park S; Kim TY; Shong YK; Kim WB; Kim K; Kim WG; Song DE
    Thyroid; 2018 Apr; 28(4):504-510. PubMed ID: 29439609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive survey of HRAS, KRAS, and NRAS mutations in proliferative thyroid lesions from an ethnically diverse population.
    Schulten HJ; Salama S; Al-Ahmadi A; Al-Mansouri Z; Mirza Z; Al-Ghamdi K; Al-Hamour OA; Huwait E; Gari M; Al-Qahtani MH; Al-Maghrabi J
    Anticancer Res; 2013 Nov; 33(11):4779-84. PubMed ID: 24222113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detecting N-RAS Q61R Mutated Thyroid Neoplasias by Immunohistochemistry.
    Crescenzi A; Fulciniti F; Bongiovanni M; Giovanella L; Trimboli P
    Endocr Pathol; 2017 Mar; 28(1):71-74. PubMed ID: 28064410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification and evaluation of novel serum autoantibody biomarkers for early diagnosis of gastric cancer and precancerous lesion.
    Zhu Q; He P; Zheng C; Chen Z; Qi S; Zhou D; Li Y; Ouyang Q; Zi H; Tang H; Xing J; Xie Y; Zhu S; Ren J; Huang J
    J Cancer Res Clin Oncol; 2023 Sep; 149(11):8369-8378. PubMed ID: 37079049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.